DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

September 6, 2000

Dear Pregnancy Labeling Subcommittee Members and Guests:

Enclosed please find a second mailing of materials for the **September 12, 2000** morning meeting of the Pregnancy Labeling Subcommittee. The meeting will convene at 10:00 am at the Hyatt Regency Bethesda.

The following additional documents are included in this package:

- Federal Register Notice announcing the meeting
- Draft meeting Agenda
- Background and Discussion Questions for the Subcommittee
- List of Pregnancy "Category D" products from the current on-line PDR

I wanted to also let you know that if you are staying at the Bethesda Holiday Inn the evening before the meeting, we will have a shuttle bus available in the morning to take you to the Hyatt Regency Bethesda for the meeting. Alternatively, the Hyatt is a five (5) block walk south down Wisconsin Avenue from the Holiday Inn. This shuttle will leave the Holiday Inn at 9:30am. Please meet at the Holiday Inn front desk no later than 9:25 a.m. I would advise that you check out of the hotel at that time and bring your luggage with you because there will not be time during the noon lunch hour to do so.

Please do not hesitate to contact me if you have any general meeting questions. You should have already received meeting travel documents from this office. Questions specifically about travel can be directed to Rebecca Diaz. Our general telephone number is (301) 827-7001.

I look forward to a very interesting meeting.

Sincerely,

Jayne E. Peterson, R.Ph., J.D.
Health Science Administrator/Subcommittee Executive Secretary
Advisors and Consultants Staff
Center for Drug Evaluation and Research (CDER)
Food and Drug Administration
(301) 827-7001 (301) 827-6776 (fax)

Enclosures

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee for Reproductive Health Drugs; Pregnancy Labeling Subcommittee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Advisory Committee for Reproductive Health Drugs; Pregnancy Labeling Subcommittee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on September 12, 2000, 10 a.m. to 12m.

Location: Hyatt Regency, One Bethesda Metro Center, Bethesda, MD.

Contact Person: Jayne E. Peterson, R.Ph., J.D., Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5630 Fishers Lane, Rockville, MD 20857, 301-827-7001, or by e-mail at PETERSONJ@CDER.FDA.GOV, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12537. Please call the Information Line for up-to-date information on this meeting.

Agenda: The Subcommittee will meet to identify and discuss those drug and biologic products for which improved pregnancy labeling is critical for (1) effective prescribing during pregnancy, or (2) proper counseling of pregnant women who have been inadvertently exposed.

Procedure: Interested persons may present data, information, or views, orally or in writing on issues pending before the subcommittee. Written submissions may be made to the contact person by September 6, 2000. Oral presentations from the public will be scheduled between approximately 11 a.m. and 12m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before September 6, 2000, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated August 4, 2000

Karen M. Templeton-Somers for
Jayne Peterson, R.Ph., J.D.
Executive Secretary

Food and Drug Administration
Center for Drug Evaluation and Research

Pregnancy Labeling Subcommittee of the Advisory Committee for Reproductive Health Drugs
Hyatt Regency, One Metro Center, Bethesda, Maryland

DRAFT AGENDA

Tuesday, September 12, 2000, 10:00 a.m. – 12:00 noon

Issue: Identification and discussion of those drug and biologic products for which improved pregnancy labeling is critical for
(1) effective prescribing during pregnancy, or
(2) proper counseling of pregnant women who have been inadvertently exposed

10:00 a.m. **Call to Order/Introductions**
Michael Greene, M.D., Chair, Pregnancy Labeling Subcommittee

Conflict of Interest Statement
Jayne Peterson, R.Ph., J.D., Executive Secretary Pregnancy Labeling Subcommittee, FDA

10:10 a.m. **Background Information and Overview**
Sandra L. Kweder, M.D., Acting Director, Office of Drug Evaluation IV, and Co-Chair, Pregnancy Labeling Task Force, FDA

10:15 a.m. **Setting Priorities for Implementing the Pregnancy Labeling Rule**
Dianne L. Kennedy, R.Ph., M.P.H
Pregnancy Labeling Initiative, FDA

10:40 a.m. **Subcommittee Discussion of Issues**

11:00 a.m. **Open Public Hearing**
(**60 minutes allocated unless public participation does not last that long.)

11:55 a.m. **Closing Remarks**
Sandra Kweder, M.D.

12:00 noon **Adjourn**

Food and Drug Administration
Center for Drug Evaluation and Research

Pregnancy Labeling Subcommittee of the Advisory Committee for Reproductive Health Drugs

Hyatt Regency, One Metro Center, Bethesda, Maryland

Tuesday, September 12, 2000, 10am – 12pm

BACKGROUND & DRAFT QUESTIONS TO THE SUBCOMMITTEE

BACKGROUND

General Implementation Plan to Revise Pregnancy Labeling : The agency is currently in the process of changing the general format of labeling for all prescription drugs. Because of anticipated resource demands on industry to develop revised labeling and on the agency to review and approve revised labeling, the implementation plan will phase in the new format requirement over a period of several years. Under the plan that will be proposed, when drugs have to have revised labeling will be determined based on date of approval. The rule would apply to newer drugs first, starting with those yet to be approved. Fairly old drugs would not have revised labeling for many years, if at all. For the rule to revise pregnancy labeling, the tentative plan is to require that, for most products, revisions to pregnancy labeling occur at the same time as revisions to the general format.

Accelerated Implementation Plan for Products Considered to be High Priority: The agency is also considering an accelerated implementation plan for certain products for which it would be important to have improved pregnancy labeling as soon as possible—products for which it would not be reasonable to wait for many years to have more informative labeling. Our preliminary thinking is that there are two general categories of products (with considerable overlap) that might benefit from an accelerated implementation plan to improve pregnancy labeling: (1) drugs to which women are likely to be inadvertently exposed during pregnancy and (2) drugs for which there is a pressing therapeutic need during pregnancy.

The agency is seeking advisory subcommittee input on whether it is worthwhile to pursue an accelerated implementation for products for which improved pregnancy labeling would seem to be a high priority and, if so, how to identify and rank products that should be high priority.

QUESTIONS

(1) In general, is an accelerated implementation plan for certain high priority products a worthwhile endeavor from a public health perspective?

(2) If so, what criteria should we use to identify priority (or non-priority) products?

(3) How would you suggest identifying specific products that meet these criteria?

Pregnancy Labeling Category D
(CFR 201.57(f)(6)(d))

If there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience of studies in humans, but the potential benefits from the use of the drug is pregnant women may be acceptable despite its potential risks (for example, if the drug is needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective). The labeling shall state:

"Pregnancy Category D. See 'Warnings' section."

Under the "Warnings" section, the labeling states:

"(Name of drug) can cause fetal harm when administered to a pregnant women. (Describe the human data and any pertinent animal data.) If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus."

CATEGORY D PRODUCTS
(SOURCE: On-line PDR 9/1/00)

Drug Name	Manufacturer
Adriamycin PFS/RDF Injection	Pharmacia & Upjohn
Aggrenox Capsules	Boehringer Ingelheim
Alkeran for Injection	Glaxo Wellcome
Alkeran Tablets	Glaxo Wellcome
Amikacin Sulfate Injection, USP	Elkins-Sinn
Arimidex Tablets	AstraZeneca
Aromasin Tablets	Pharmacia & Upjohn
Ativan Injection	Wyeth-Ayerst
BiCNU	Bristol-Myers Squibb Oncology/Immunology
Blenoxane	Bristol-Myers Squibb Oncology/Immunology
Camptosar Injection	Pharmacia & Upjohn
Carbatrol Capsules	Shire Richwood
CeeNU Capsules	Bristol-Myers Squibb Oncology/Immunology
Cerebyx Injection	Parke-Davis
Cerubidine for Injection	Bedford
Cordarone Intravenous	Wyeth-Ayerst
Cordarone Tablets	Wyeth-Ayerst
Cytosar-U Sterile Powder	Pharmacia & Upjohn
Cytoxan for Injection	Bristol-Myers Squibb Oncology/Immunology
DaunoXome Injection	Gilead
Depacon Injection	Abbott
Depakene Capsules	Abbott
Depakote Sprinkle Capsules	Abbott
Depakote Tablets	Abbott
DepoCyt Injection	Chiron
Diastat Rectal Delivery System	Elan
Doxil Injection	Alza
Droxia Capsules	Bristol-Myers Squibb Oncology/Immunology
Dynacin Capsules	Medicis
Ellence Injection	Pharmacia & Upjohn
Etopophos for Injection	Bristol-Myers Squibb Oncology/Immunology
Eulexin Capsules	Schering
Fareston Tablets	SCHERING CORPORATION
Fludara for Injection	Berlex
Gemzar for Injection	Lilly
Gliadel Wafer	Rhone-Poulenc Rorer
Hexalen Capsules	U.S. Bioscience
Hycamtin for Injection	SmithKline Beecham
Idamycin PFS Injection	Pharmacia & Upjohn
Ifex for Injection	Bristol-Myers Squibb Oncology/Immunology
Imuran Injection	Faro
Klonopin Tablets	Roche Laboratories
Leukeran Tablets	Glaxo Wellcome
Leustatin Injection	Ortho Biotech
Lithium Carbonate Capsules & Tablets	Roxane
Lithobid Slow-Release Tablets	Solvay
Matulane Capsules	sigma-tau
Mebaral Tablets	Sanofi
Megace Tablets	Bristol-Myers Squibb Oncology/Immunology
Minocin Pellet-Filled Capsules	Lederle Consumer

Monodox Capsules	Oclassen
Mustargen for Injection	Merck
Myleran Tablets	Glaxo Wellcome
Navelbine Injection	Glaxo Wellcome
Nebcin Vials, Hyporets & ADD-Vantage	Lilly
Nembutal Sodium Capsules	Abbott
Nembutal Sodium Solution	Abbott
Nembutal Sodium Suppositories	Abbott
Neosporin G.U. Irrigant Sterile	Monarch
Netromycin Injection 100 mg/ml	SCHERING CORPORATION
Neutrexin for Injection	U.S. Bioscience
Nicotrol Inhaler	McNeil Consumer
Nicotrol Nasal Spray	McNeil Consumer
Nipent for Injection	SuperGen
Nolvadex Tablets	AstraZeneca
Novantrone for Injection	Immunex
Oncovin Solution Vials	Lilly
Pacerone Tablets	Upsher-Smith
Panretin Gel	Ligand
Paraplatin for Injection	Bristol-Myers Squibb Oncology/Immunology
Periostat Capsules	CollaGenex
Platinol-AQ Injection	Bristol-Myers Squibb Oncology/Immunology
Purinethol Tablets	Glaxo Wellcome
Rubex for Injection	Bristol-Myers Squibb Oncology/Immunology
Sterile FUDR	Roche Laboratories
Streptomycin Sulfate Injection	Pfizer
Taxol Injection	Bristol-Myers Squibb Oncology/Immunology
Taxotere for Injection Concentrate	Aventis
Tegretol Chewable Tablets	Novartis
Temodar Capsules	Schering
Tenoretic Tablets	AstraZeneca
Tenormin I.V. Injection	AstraZeneca
Thioguanine Tablets, Tabloid Brand	Glaxo Wellcome
Thioplex for Injection	Immunex
TOBI Solution for Inhalation	Pathogenesis
Vectrin Capsules	Warner Chilcott
Velban Vials	Lilly
VePesid for Injection	Bristol-Myers Squibb Oncology/Immunology
Versed Injection	Roche Laboratories
Versed Syrup	Roche Laboratories
Vesanoid Capsules	Roche Laboratories
Vibramycin Monohydrate for Oral Suspension	Pfizer
Vumon for Injection	Bristol-Myers Squibb Oncology/Immunology
Xanax Tablets	Pharmacia & Upjohn
Xeloda Tablets	Roche Laboratories
Zanosar Sterile Powder	Pharmacia & Upjohn
Zoladex	AstraZeneca